A unique new radioimmunotherapeutic conjugate,131I anti-B1 antibody [B1, ‘Bexxar’; Coulter Pharmaceuticals], appears to offer an effective, well tolerated, and less costly approach for the treatment of patients with low-grade, and transformed low-grade, B-cell non-Hodgkin's lymphoma (NHL). The latest developments with this targeted therapy approach were presented at the 39th Annual Meeting & Exposition of the American Society of Hematology [San Diego, US; December 1997].